By PPN News Staff
The FDA granted approval for an expanded indication for the poly(adenosine diphosphate–ribose) polymerase inhibitor niraparib (Zejula, GlaxoSmithKline): treatment of patients with advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status (either with a BRCA mutation that is deleterious/suspected to be